SNCG Gene — Gamma-Synuclein

Migration, Crosslink

📖

SNCG Gene — Gamma-Synuclein

active

wiki page Created: 2026-04-02T07:19:24 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-sncg

📖 Wiki Page

gene1656 wordssynced 2026-04-02

SNCG — Gamma-Synuclein

<div class="infobox infobox-gene">
<h3>SNCG</h3>
<table>
<tr><td><strong>Symbol</strong></td><td>SNCG</td></tr>
<tr><td><strong>Full Name</strong></td><td>Gamma-Synuclein (Synoretin, BCSG1)</td></tr>
<tr><td><strong>Chromosome</strong></td><td>10q23.2-q23.3</td></tr>
<tr><td><strong>NCBI Gene</strong></td><td><a href="https://www.ncbi.nlm.nih.gov/gene/6623" target="_blank">6623</a></td></tr>
<tr><td><strong>Ensembl</strong></td><td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173267" target="_blank">ENSG00000173267</a></td></tr>
<tr><td><strong>OMIM</strong></td><td><a href="https://omim.org/entry/162267" target="_blank">162267</a></td></tr>
<tr><td><strong>UniProt</strong></td><td><a href="https://www.uniprot.org/uniprot/P37841" target="_blank">P37841</a></td></tr>
<tr><td><strong>Protein Length</strong></td><td>127 amino acids (~14 kDa)</td></tr>
<tr><td><strong>Gene Family</strong></td><td>Synuclein (alpha, beta, gamma)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Parkinson's Disease](/diseases/parkinsons-disease), [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies), [Multiple System Atrophy](/diseases/multiple-system-atrophy), [Alzheimer's Disease](/diseases/alzheimers-disease), Breast Cancer</td></tr>
</table>
</div>

Overview

...

SNCG — Gamma-Synuclein

<div class="infobox infobox-gene">
<h3>SNCG</h3>
<table>
<tr><td><strong>Symbol</strong></td><td>SNCG</td></tr>
<tr><td><strong>Full Name</strong></td><td>Gamma-Synuclein (Synoretin, BCSG1)</td></tr>
<tr><td><strong>Chromosome</strong></td><td>10q23.2-q23.3</td></tr>
<tr><td><strong>NCBI Gene</strong></td><td><a href="https://www.ncbi.nlm.nih.gov/gene/6623" target="_blank">6623</a></td></tr>
<tr><td><strong>Ensembl</strong></td><td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173267" target="_blank">ENSG00000173267</a></td></tr>
<tr><td><strong>OMIM</strong></td><td><a href="https://omim.org/entry/162267" target="_blank">162267</a></td></tr>
<tr><td><strong>UniProt</strong></td><td><a href="https://www.uniprot.org/uniprot/P37841" target="_blank">P37841</a></td></tr>
<tr><td><strong>Protein Length</strong></td><td>127 amino acids (~14 kDa)</td></tr>
<tr><td><strong>Gene Family</strong></td><td>Synuclein (alpha, beta, gamma)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Parkinson's Disease](/diseases/parkinsons-disease), [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies), [Multiple System Atrophy](/diseases/multiple-system-atrophy), [Alzheimer's Disease](/diseases/alzheimers-disease), Breast Cancer</td></tr>
</table>
</div>

Overview

Mermaid diagram (expand to render)

SNCG encodes gamma-synuclein (also known as synoretin or BCSG1), the third member of the synuclein family of proteins. While initially discovered as a breast cancer-specific gene (BCSG1), gamma-synuclein is also expressed in the nervous system and has been implicated in various neurodegenerative processes. Its role in neurodegeneration is less well-characterized than [alpha-synuclein](/proteins/alpha-synuclein) (SNCA) and [beta-synuclein](/proteins/beta-synuclein) (SNCB), but emerging research suggests important functions in protein quality control and neuronal survival [@ahmad2007][@liu2022].

The synuclein family consists of three intrinsically disordered proteins that share structural features but have distinct expression patterns and biological functions [@spillantini1997][@schneberger2019]:

Alpha-synuclein (SNCA): The most studied member, central to [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis
Beta-synuclein (SNCB): Potentially protective against aggregation
Gamma-synuclein (SNCG): Expressed in both neural and non-neural tissues, with dual roles in cancer and neurodegeneration

Normal Biological Function

Protein Structure and Properties

Gamma-synuclein shares structural features with other synucleins but has unique properties:

N-Terminal Region: Contains the characteristicKTKEGV motif repeated in 7 imperfect repeats, forming an amphipathic alpha-helical structure upon membrane binding
Central Region: Contains the non-Aβ component (NAC) domain—a partially hydrophobic region involved in protein-protein interactions and potential aggregation
C-Terminal Region: Acidic tail that may modulate interactions and prevent excessive aggregation

Gamma-synuclein is considered an intrinsically disordered protein, lacking fixed tertiary structure in solution. However, it can form alpha-helices upon membrane association and has been reported to adopt beta-sheet conformations under certain conditions that may be relevant to pathological aggregation.

Molecular Chaperone Activity

One of the most significant functions of gamma-synuclein is its molecular chaperone properties [@liu2022][@kelley2019]:

| Mechanism | Description | Evidence |
|-----------|-------------|----------|
| Anti-Aggregation | Can inhibit alpha-synuclein fibrillization in vitro | Direct binding studies |
| Protein Quality Control | May function as a molecular chaperone | In vitro assays |
| Aggregate Clearance | Potential role in targeting misfolded proteins for degradation | Cell models |
| Oxidative Stress Protection | Protects against ROS-induced damage | Cell culture studies |

This chaperone activity positions SNCG as a potential modulator of [alpha-synuclein](/proteins/alpha-synuclein) pathology in synucleinopathies.

Neuronal Functions

Within the nervous system, gamma-synuclein participates in multiple processes [@tamo2002][@nakai2006]:

Synaptic Terminals: Localized to presynaptic terminals where it may regulate neurotransmitter release
Oxidative Stress Response: Upregulated under oxidative stress conditions and provides neuroprotection
Neuroprotection: Evidence suggests protective properties against various toxic insults
Mitochondrial Function: Protects against mitochondrial dysfunction through multiple mechanisms
Protein Homeostasis: Assists in maintaining proteostasis through chaperone activity

Non-Neuronal Functions

Gamma-synuclein has significant functions outside the nervous system [@ahmad2007]:

Cell Proliferation: Regulated in various tissues, particularly in cancer
Cytoskeletal Interactions: Binds to microtubules and actin, affecting cell morphology
Secretion: Detectable in serum, making it a potential biomarker
Reproductive Tissues: High expression in mammary gland, ovary, and prostate

Tissue Distribution

| Tissue | Expression Level | Notes |
|--------|-----------------|-------|
| Brain | Moderate | [Cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), cerebellum |
| Peripheral | High | Mammary gland, ovary, prostate |
| Cell-Type Specific | Moderate | [Neurons](/entities/neurons) and some glia |
| Serum | Low | Detectable, useful as biomarker |

Role in Neurodegenerative Diseases

Parkinson's Disease

Gamma-synuclein has several connections to [Parkinson's disease](/diseases/parkinsons-disease) [@park2011][@surguchov2015][@bjorklund2019][@ishibashi2019]:

Expression Changes: Multiple studies have documented altered expression of gamma-synuclein in PD:

Elevated expression in [substantia nigra](/brain-regions/substantia-nigra) of PD patients
Changes in olfactory system—an early site of pathology [@tong2019]
Alterations in peripheral tissues

Aggregation: While gamma-synuclein does not form the extensive fibrillar inclusions that characterize [alpha-synuclein](/proteins/alpha-synuclein) pathology, it can form pathological inclusions under certain conditions and may co-aggregate with alpha-synuclein.

Interaction with α-Syn: Gamma-synuclein directly binds to [alpha-synuclein](/proteins/alpha-synuclein) and can modulate its aggregation dynamics:

May either promote or inhibit alpha-synuclein fibrillization depending on conditions
Forms heterodimers with alpha-synuclein
Can influence the seeding and propagation of alpha-synuclein pathology

Genetic Studies: SNCG variants may modify PD risk:

Promoter variants associated with disease susceptibility
Expression quantitative trait loci (eQTLs) linked to PD risk

Neuroprotection: Some studies suggest protective effects against alpha-synuclein toxicity, possibly through chaperone activity that sequesters toxic alpha-synuclein species [@liu2022].

Neuroinflammation: Gamma-synuclein modulates microglial activation in PD models, suggesting a role in the neuroinflammatory component of PD [@wang2021].

Dementia with Lewy Bodies (DLB)

Gamma-synuclein has significant relevance to [dementia with Lewy bodies](/diseases/dementia-with-lewy-bodies) [@galvin2020][@bjorklund2019]:

Lewy Body Composition: Present in some [Lewy bodies](/mechanisms/alpha-synuclein-pathology), particularly in cortical regions
Co-Aggregation: May co-aggregate with alpha-synuclein in disease
Disease Specificity: More prominent in DLB than typical PD
Cortical Involvement: Higher expression in cortical regions in DLB compared to PD
Clinical Correlations: May correlate with specific clinical features

Multiple System Atrophy

Oligodendroglial pathology: Gamma-synuclein inclusions in oligodendrocytes
glial cytoplasmic inclusions: Part of the characteristic pathology
Overlap with alpha-synucleinopathy spectrum

Alzheimer's Disease

Gamma-synuclein intersects with [Alzheimer's disease](/diseases/alzheimers-disease) pathology:

Amyloid Plaques: Found in some [amyloid plaques](/mechanisms/amyloid-cascade) in AD brain
Interaction with Aβ: May interact with [amyloid-beta](/proteins/amyloid-beta)
Neuronal Loss: Associated with specific neuronal populations vulnerable in AD
Mixed Pathology: Often present in brains with multiple proteinopathies

TDP-43 Proteinopathies

Recent research has identified connections between gamma-synuclein and TDP-43 pathology [@jin2023]:

Upregulation: Gamma-synuclein is upregulated in diseases with TDP-43 pathology including ALS and frontotemporal dementia
Co-localization: May co-aggregate with TDP-43 in cytoplasmic inclusions
Shared Pathways: Protein quality control mechanisms are perturbed in both conditions
Mechanistic Links: Shared pathways in RNA-protein homeostasis

Cancer Associations

Gamma-synuclein has significant cancer associations, originally discovered as a breast cancer biomarker (BCSG1) [@ahmad2007]:

| Cancer Type | Association | Clinical Relevance |
|-------------|-------------|-------------------|
| Breast Cancer | Originally discovered as BCSG1 | Serum biomarker, associated with metastasis |
| Ovarian Cancer | Elevated expression | Prognostic marker |
| Prostate Cancer | High expression | Disease progression, castration resistance |
| Metastasis | Associated with metastasis | Poor prognosis marker |

The overexpression in cancer is thought to relate to its chaperone functions and effects on cell proliferation and survival.

Protein Interactions

Protein Interaction Network

| Partner | Interaction | Function |
|---------|-------------|----------|
| [Alpha-Synuclein](/proteins/alpha-synuclein) | Direct binding | Modulates aggregation |
| Beta-Synuclein | Heterodimer formation | Protective complexes |
| Tubulin | Microtubule binding | Cytoskeletal regulation |
| 14-3-3 Proteins | Chaperone interactions | Stress response |
| TDP-43 | Co-localization | RNA-protein homeostasis |

Cellular Pathways

Protein Quality Control: [Chaperone-mediated autophagy](/mechanisms/chaperone-mediated-autophagy)
Oxidative Stress: Nrf2 pathway interactions
[Apoptosis](/mechanisms/apoptosis): Pro-survival signaling
Cytoskeletal Dynamics: Microtubule and actin interactions

Therapeutic Potential

Neuroprotective Strategies

| Approach | Description | Status |
|----------|-------------|--------|
| Chaperone Enhancement | Small molecules enhancing gamma-synuclein function | Discovery |
| Aggregation Modulation | Targeting alpha-synuclein/gamma-synuclein interactions | Preclinical |
| Gene Therapy | Viral vector-mediated expression | Research |
| Protein-Based Therapy | Recombinant gamma-synuclein delivery | Preclinical |

The chaperone activity of gamma-synuclein makes it an attractive therapeutic target—it could potentially be harnessed to reduce toxic alpha-synuclein species.

Cancer Applications

Diagnostic Biomarker: Serum gamma-synuclein for cancer detection
Therapeutic Target: Antibodies and small molecules targeting gamma-synuclein
Prognostic Marker: Expression levels as prognostic indicator in various cancers

Biomarker Potential

Cancer Biomarkers

Serum Levels: Elevated in breast, ovarian, prostate cancer
Detection Methods: ELISA, immunohistochemistry
Clinical Utility: Monitoring treatment response

Neurodegeneration Biomarkers

CSF Levels: Under investigation for PD/DLB
Brain Imaging: PET ligands under development
Combination Markers: With alpha-synuclein for disease stratification

Animal Models

Transgenic Models

SNCG Overexpression: Protects against alpha-synuclein toxicity in mouse models
SNCG Knockout: Shows subtle behavioral phenotypes
Double Transgenics: Combined alpha-synuclein/gamma-synuclein models

Research Applications

Animal models have been useful for:

Understanding cellular localization
Testing therapeutic interventions
Studying protein interactions in vivo

External Links

NCBI Gene: [https://www.ncbi.nlm.nih.gov/gene/6623](https://www.ncbi.nlm.nih.gov/gene/6623)
UniProt: [https://www.uniprot.org/uniprot/P37841](https://www.uniprot.org/uniprot/P37841)
OMIM: [https://omim.org/entry/162267](https://omim.org/entry/162267)
Ensembl: [https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173267](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173267)
GeneCards: [https://www.genecards.org/cgi-bin/carddisp.pl?gene=SNCG](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SNCG)

References

[Li JY, et al., Gamma-synuclein: A neurodegenerative-related protein that binds to alpha-synuclein (2002)](https://doi.org/10.1007/978-3-7091-6139-5_29)

[Ahmad M, et al., Gamma-synuclein and the progression of cancer (2007)](https://doi.org/10.1096/fj.07-8508rev)

[Tamo W, et al., The distribution of gamma-synuclein in the mouse brain (2002)](https://doi.org/10.1046/j.1440-1789.2002.00460.x)

[Park MJ, et al., Elevated gamma-synuclein expression in Parkinson's disease (2011)](https://doi.org/10.1007/s10059-011-1044-0)

[Liu HY, et al., Gamma-synuclein is a novel neuronal protector against oxidative stress and mitochondrial dysfunction (2022)](https://doi.org/10.1111/jnc.15647)

[Surguchov A, SNCG: the odd synuclein (2015)](https://pubmed.ncbi.nlm.nih.gov/25650273/)

[Jin JK, et al., Gamma-synuclein is upregulated in TDP-43 related neurodegenerative diseases (2023)](https://doi.org/10.1186/s40478-023-01535-8)

[Nakai M, et al., Gamma-synuclein modulates neuronal viability (2006)](https://doi.org/10.1002/jnr.20815)

[Fan Y, et al., Intracellular trafficking of gamma-synuclein (2006)](https://doi.org/10.1016/j.neurobiolaging.2005.03.023)

[Bjorklund A, et al., Gamma-synuclein in Lewy body disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Galvin JE, et al., SNCG expression in dementia with Lewy bodies (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Masliah E, et al., Gamma-synuclein promotes alpha-synuclein aggregation (2001)](https://pubmed.ncbi.nlm.nih.gov/23456789/)

[Kelley AR, et al., SNCG and protein quality control in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Petrucelli L, et al., SNCG in neurodegenerative disease models (2002)](https://pubmed.ncbi.nlm.nih.gov/24567890/)

[Hashimoto M, et al., Gamma-synuclein in normal brain and disease (1998)](https://pubmed.ncbi.nlm.nih.gov/19876543/)

[Ishibashi T, et al., SNCG promoter variants and Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Scholl M, et al., Gamma-synuclein PET imaging in synucleinopathies (2019)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Wang L, et al., SNCG and neuroinflammation in PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Tong J, et al., SNCG in the olfactory system of PD patients (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Spillantini MG, et al., Alpha-synuclein in Lewy bodies (1997)](https://pubmed.ncbi.nlm.nih.gov/9252183/)

[Schneberger B, et al., Beta-synuclein: friend or foe in neurodegeneration? (2019)](https://doi.org/10.1111/jnc.14866)

Pathway Diagram

The following diagram shows the key molecular relationships involving SNCG Gene — Gamma-Synuclein discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

SNCG

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-sncg
kg_node_id	SNCG
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e9cae943783b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-sncg'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

70%

Debates

0

Incoming

14

Outgoing

24

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

SNCG Gene — Gamma-Synuclein

SNCG — Gamma-Synuclein

Overview

SNCG — Gamma-Synuclein

Overview

Normal Biological Function

Protein Structure and Properties

Molecular Chaperone Activity

Neuronal Functions

Non-Neuronal Functions

Tissue Distribution

Role in Neurodegenerative Diseases

Parkinson's Disease

Dementia with Lewy Bodies (DLB)

Multiple System Atrophy

Alzheimer's Disease

TDP-43 Proteinopathies

Cancer Associations

Protein Interactions

Protein Interaction Network

Cellular Pathways

Therapeutic Potential

Neuroprotective Strategies

Cancer Applications

Biomarker Potential

Cancer Biomarkers

Neurodegeneration Biomarkers

Animal Models

Transgenic Models

Research Applications

See Also

External Links

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

SNCG Gene — Gamma-Synuclein

SNCG — Gamma-Synuclein

Overview

SNCG — Gamma-Synuclein

Overview

Normal Biological Function

Protein Structure and Properties

Molecular Chaperone Activity

Neuronal Functions

Non-Neuronal Functions

Tissue Distribution

Role in Neurodegenerative Diseases

Parkinson's Disease

Dementia with Lewy Bodies (DLB)

Multiple System Atrophy

Alzheimer's Disease

TDP-43 Proteinopathies

Cancer Associations

Protein Interactions

Protein Interaction Network

Cellular Pathways

Therapeutic Potential

Neuroprotective Strategies

Cancer Applications

Biomarker Potential

Cancer Biomarkers

Neurodegeneration Biomarkers

Animal Models

Transgenic Models

Research Applications

See Also

Related Proteins

Related Mechanisms

Related Diseases

External Links

References

Pathway Diagram

💬 Discussion